Sclerostin modulation holds promise for dental indications

Mohamed G. Hassan; Abbas R. Zaher; Juan Martin Palomo; Leena Palomo

doi:10.3390/healthcare6040134

Sclerostin modulation holds promise for dental indications

Mohamed G. Hassan, Abbas R. Zaher, Juan Martin Palomo, Leena Palomo

Periodontology and Implant Dentistry

Research output: Contribution to journal › Review article › peer-review

Abstract

Sclerostin modulation is a novel therapeutic bone regulation strategy. The anti-sclerostin drugs, proposed in medicine for skeletal bone loss may be developed for jaw bone indications in dentistry. Alveolar bone responsible for housing dentition share common bone remodeling mechanisms with skeletal bone. Manipulating alveolar bone turnover can be used as a strategy to treat diseases such as periodontitis, where large bone defects from disease are a surgical treatment challenge and to control tooth position in orthodontic treatment, where moving teeth through bone in the treatment goal. Developing such therapeutics for dentistry is a future line for research and therapy. Furthermore, it underscores the interprofessional relationship that is the future of healthcare.

Original language	English (US)
Article number	134
Journal	Healthcare (Switzerland)
Volume	6
Issue number	4
DOIs	https://doi.org/10.3390/healthcare6040134
State	Published - Dec 2018

Keywords

Alveolar bone
Anti-sclerostin
Bone loss
Bone remodeling
Orthodontic
Periodontitis
Sclerostin
Tooth movement

ASJC Scopus subject areas

Leadership and Management
Health Policy
Health Informatics
Health Information Management

Access to Document

10.3390/healthcare6040134

Cite this

@article{6ad45e313d414d6bb4c8211ff39f2db0,

title = "Sclerostin modulation holds promise for dental indications",

abstract = "Sclerostin modulation is a novel therapeutic bone regulation strategy. The anti-sclerostin drugs, proposed in medicine for skeletal bone loss may be developed for jaw bone indications in dentistry. Alveolar bone responsible for housing dentition share common bone remodeling mechanisms with skeletal bone. Manipulating alveolar bone turnover can be used as a strategy to treat diseases such as periodontitis, where large bone defects from disease are a surgical treatment challenge and to control tooth position in orthodontic treatment, where moving teeth through bone in the treatment goal. Developing such therapeutics for dentistry is a future line for research and therapy. Furthermore, it underscores the interprofessional relationship that is the future of healthcare.",

keywords = "Alveolar bone, Anti-sclerostin, Bone loss, Bone remodeling, Orthodontic, Periodontitis, Sclerostin, Tooth movement",

author = "Hassan, {Mohamed G.} and Zaher, {Abbas R.} and Palomo, {Juan Martin} and Leena Palomo",

note = "Publisher Copyright: {\textcopyright} 2018 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2018",

month = dec,

doi = "10.3390/healthcare6040134",

language = "English (US)",

volume = "6",

journal = "Healthcare (Switzerland)",

issn = "2227-9032",

publisher = "MDPI AG",

number = "4",

}

TY - JOUR

T1 - Sclerostin modulation holds promise for dental indications

AU - Hassan, Mohamed G.

AU - Zaher, Abbas R.

AU - Palomo, Juan Martin

AU - Palomo, Leena

PY - 2018/12

Y1 - 2018/12

N2 - Sclerostin modulation is a novel therapeutic bone regulation strategy. The anti-sclerostin drugs, proposed in medicine for skeletal bone loss may be developed for jaw bone indications in dentistry. Alveolar bone responsible for housing dentition share common bone remodeling mechanisms with skeletal bone. Manipulating alveolar bone turnover can be used as a strategy to treat diseases such as periodontitis, where large bone defects from disease are a surgical treatment challenge and to control tooth position in orthodontic treatment, where moving teeth through bone in the treatment goal. Developing such therapeutics for dentistry is a future line for research and therapy. Furthermore, it underscores the interprofessional relationship that is the future of healthcare.

AB - Sclerostin modulation is a novel therapeutic bone regulation strategy. The anti-sclerostin drugs, proposed in medicine for skeletal bone loss may be developed for jaw bone indications in dentistry. Alveolar bone responsible for housing dentition share common bone remodeling mechanisms with skeletal bone. Manipulating alveolar bone turnover can be used as a strategy to treat diseases such as periodontitis, where large bone defects from disease are a surgical treatment challenge and to control tooth position in orthodontic treatment, where moving teeth through bone in the treatment goal. Developing such therapeutics for dentistry is a future line for research and therapy. Furthermore, it underscores the interprofessional relationship that is the future of healthcare.

KW - Alveolar bone

KW - Anti-sclerostin

KW - Bone loss

KW - Bone remodeling

KW - Orthodontic

KW - Periodontitis

KW - Sclerostin

KW - Tooth movement

UR - http://www.scopus.com/inward/record.url?scp=85114070277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114070277&partnerID=8YFLogxK

U2 - 10.3390/healthcare6040134

DO - 10.3390/healthcare6040134

M3 - Review article

AN - SCOPUS:85114070277

SN - 2227-9032

VL - 6

JO - Healthcare (Switzerland)

JF - Healthcare (Switzerland)

IS - 4

M1 - 134

ER -

Sclerostin modulation holds promise for dental indications

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this